illumina

Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum

Summary: 

New sequencing technologies and capabilities will accelerate the genomic discoveries and clinical insights needed to transform human health

Revolutionary NovaSeq X Series sets new benchmark for speed, scale, accuracy, and sustainability

Press Release

New sequencing technologies and capabilities will accelerate the genomic discoveries and clinical insights needed to transform human health

Revolutionary NovaSeq X Series sets new benchmark for speed, scale, accuracy, and sustainability

Illumina Unveils Revolutionary NovaSeq X Series To Rapidly Accelerate Genomic Discoveries and Improve Human Health

Summary: 

New technology enables highest levels of accuracy at immense scale, with the power to sequence more than 20,000 genomes per year

Our most sustainable high-throughput sequencer delivers 90% reduction in packaging and 50% reduction in plastic waste, and eliminates dry ice shipments, expanding global access to genomic medicine

Press Release

New technology enables highest levels of accuracy at immense scale, with the power to sequence more than 20,000 genomes per year

Our most sustainable high-throughput sequencer delivers 90% reduction in packaging and 50% reduction in plastic waste, and eliminates dry ice shipments, expanding global access to genomic medicine

How Comprehensive Genomic Profiling Is Helping Cancer Patients Today

At ESMO 2022 in Paris, oncologists discussed real-world cases and big-picture challenges
Article

The European Society of Medical Oncology (ESMO) annual congress convened earlier this month in Paris, where, Illumina presented key abstracts demonstrating the clinical utility of comprehensiv

Illumina Grant Boosts Climate Action and Job Training

US nonprofit GRID Alternatives launches new projects to provide renewable energy
Article

As part of Illumina’s long-term commitment to sustainability, the Illumina Corporate Foundation made a one-year, $500,000 grant to support GRID Alternatives (Generating Renewable Ideas and Development Alternatives), a nonprofit committed to increasing access to renewable energy and training people for clean energy jobs.

Illumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications

Six startups from Indonesia, Ireland, Israel, South Africa, United Kingdom and the United States will receive seed investment and access to technology and expertise
Press Release

SAN DIEGO, September 14, 2022 /3BL Media/ - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it has invested in six genomics startups for the fifth global funding cycle of Illumina Accelerator in the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator is a world-class company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. The program also announced today the October 1, 2022 application deadline for its next funding cycle.

Illumina Genomics Forum To Feature Diverse Lineup of Visionary Global Leaders

Full agenda now available for September 28–October 1 event
Press Release

SAN DIEGO, September 12, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced the release of the full agenda for its inaugural Illumina Genomics Forum. The agenda for the four-day event can be seen here.

Latest Research at ESMO Congress 2022 Showcases the Impact of Comprehensive Genomic Profiling for Cancer Patients

Presentations will include evidence on how genomic signatures and next-generation sequencing can improve the care of patients with cancer
Press Release

SAN DIEGO, September 7, 2022 / 3BL Media / — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced the upcoming presentation of multiple oncology research abstracts at this year’s European Society of Medical Oncology (ESMO) annual meeting, September 9–13 in Paris. The abstracts underscore the value of next-generation sequencing (NGS) and Illumina’s oncology assays for cancer research and patient care.

Delivering the Future of Diagnostics and Precision Oncology

At ECP 2022, Illumina presents new validation for TSO Comprehensive
Article

At the 34th European Congress of Pathology (ECP) in Basel, Switzerland, September 3 to 7, 2022, pathologists from more than 100 countries will convene to share and gain insights on advancements in their field. Illumina Director of Product Development Victor Sementchenko will deliver a presentation during the session, Molecular Pathology Diagnostics and Translational Research Symposium.

Illumina Deepens Commitment to Customers in China With New Manufacturing Site

Investment in new Shanghai-based facility will allow the company to better serve its customers and meet growing demand
Press Release

SAN DIEGO, August 31, 2022 /3BL Media/ - Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of its first manufacturing site in China. The new Shanghai-based facility enables localized production for Illumina's gene sequencing instruments and consumables and reflects the growing demand in the Chinese market for Illumina's systems and products.

Discovery Education and Illumina Corporate Foundation Present a New Virtual Field Trip for Students To Explore the Power of DNA

Press Release

CHARLOTTE, N.C., September 6, 2022 /3BL Media/ — Discovery Education and The Illumina Corporate Foundation today announced a new virtual experience – Genomics: Decoding the Language of Life Virtual Field Trip – to immerse students in grades 6-12 in the power of DNA. Presented by the Illumina Corporate Foundation and Discovery Education, this virtual field trip is part of DNA Decoded, a program designed to inspire students to unlock the power of genomics with ready-to-go, standards-aligned lessons and activities.

Pages

Subscribe to illumina